RecruitingPhase 1NCT03198052

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Enrollment

30 participants

Start Date

Jul 1, 2017

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Cancer Immunotherapy CAR-T Cell

Summary

The third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR -CAR-T cell immunotherapy on human cancers will firstly be tested.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a type of immune cell therapy called CAR-T — where a patient's own immune cells are modified to recognise and destroy cancer cells — for people with advanced cancers that carry specific proteins on their surface, including liver cancer, stomach cancer, pancreatic cancer, and others. **You may be eligible if...** - You have advanced cancer that tests positive for one or more of several specific proteins (such as GPC3, HER2, Mesothelin, EGFR, or others listed in the study) - Your expected survival is more than 12 weeks - Your heart, lungs, liver, and kidneys are functioning adequately - Lab tests confirm your modified immune cells are working as expected **You may NOT be eligible if...** - Your tumour does not express any of the target proteins - Your organ function does not meet minimum thresholds - You have active serious infections or other serious conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR

CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.

Locations(2)

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03198052

Related Trials

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT055881411 location

Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors

NCT074543307 locations